Literature DB >> 14521809

Prognostic factors in pediatric Hodgkin disease.

Cindy L Schwartz1.   

Abstract

The sensitivity of pediatric Hodgkin disease to radiation and chemotherapy has resulted in cure for most children and adolescents who have been diagnosed in the past three decades. Identification of prognostic factors in clinical trials has allowed for tailoring of therapeutic approaches to improve outcome in sequential trials. Tumor burden, symptoms, clinical features, pathology, response to therapy, biology, and host factors are reviewed in this context. New developments should be directed toward identification of factors associated with biologic mechanisms of disease to facilitate the development of biologically targeted therapies that will be more efficacious and less toxic.

Entities:  

Mesh:

Year:  2003        PMID: 14521809     DOI: 10.1007/s11912-003-0011-0

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  51 in total

Review 1.  The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling.

Authors:  M Karin; M Delhase
Journal:  Semin Immunol       Date:  2000-02       Impact factor: 11.130

2.  PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.

Authors:  Lale Kostakoglu; Morton Coleman; John P Leonard; Ichiei Kuji; Holly Zoe; Stanley J Goldsmith
Journal:  J Nucl Med       Date:  2002-08       Impact factor: 10.057

Review 3.  Immune regulation by CD40 and its ligand GP39.

Authors:  T M Foy; A Aruffo; J Bajorath; J E Buhlmann; R J Noelle
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

4.  Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease.

Authors:  U Axdorph; J Sjöberg; G Grimfors; O Landgren; A Porwit-MacDonald; M Björkholm
Journal:  Ann Oncol       Date:  2000-11       Impact factor: 32.976

5.  In vivo somatic mutation in the lymphocytes of Hodgkin's disease patients.

Authors:  M Caggana; H L Liber; P M Mauch; C N Coleman; K T Kelsey
Journal:  Environ Mol Mutagen       Date:  1991       Impact factor: 3.216

6.  Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells.

Authors:  S S Mir; B W Richter; C S Duckett
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

7.  MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial.

Authors:  R J Hutchinson; C J Fryer; P C Davis; J Nachman; M D Krailo; R T O'Brien; R D Collins; T Whalen; D Reardon; M E Trigg; G S Gilchrist
Journal:  J Clin Oncol       Date:  1998-03       Impact factor: 44.544

8.  Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook.

Authors:  W Dörffel; H Lüders; U Rühl; M Albrecht; H Marciniak; R Parwaresch; R Pötter; G Schellong; E-W Schwarze; L Wickmann
Journal:  Klin Padiatr       Date:  2003 May-Jun       Impact factor: 1.349

9.  Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90.

Authors:  Karin Dieckmann; Richard Pötter; Johannes Hofmann; Harald Heinzl; Wolfgang Wagner; Günther Schellong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-07-01       Impact factor: 7.038

10.  Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. A study of 1659 patients.

Authors:  K A MacLennan; M H Bennett; A Tu; B V Hudson; M J Easterling; G V Hudson; A M Jelliffe
Journal:  Cancer       Date:  1989-10-15       Impact factor: 6.860

View more
  1 in total

1.  Detection of acquired hemoglobinopathy in children with hematological malignancies at disease onset: results form a national referral centre.

Authors:  Despoina N Maritsi; Helen V Kosmidis; Varvara Douna; Joanne Traeger-Synodinos; Maria N Tsolia; Lydia Kossiva
Journal:  Int J Hematol       Date:  2013-10-05       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.